Examining the role of spleen aminopeptide oral solution in the management of seasonal allergic rhinitis

According to a recent study, beginning treatment with spleen aminopeptide oral solution early on can significantly relieve nasal and eye symptoms in patients dealing with seasonal allergic rhinitis. This treatment not only lessens the reliance on medications during flare-ups but also enhances overall quality of life. It might exert an immunomodulatory effect by lowering serum levels of IL-17A in patients. These research findings have been published in journal Zhonghua Yu Fang Yi Xue Za Zhi. 
In this study, 392 patients diagnosed with seasonal allergic rhinitis were selected and randomly split into two groups: the spleen aminopeptide group, consisting of 296 patients, and a control group with 96 patients, in a 3:1 ratio. The treatment group was given an oral solution of spleen aminopeptide for a duration of 12 weeks, beginning 4 to 6 weeks (±7 days) before the onset of pollen dispersal. The control group received a simulated spleen aminopeptide solution. During the pollen dispersal period, both groups had access to oral antihistamines and/or nasal glucocorticoids as necessary. The therapeutic outcomes were evaluated by comparing drug scores, symptom scores, and quality of life scores between the two groups, as well as analyzing cytokine expression levels in the serum. The comparison of scores and laboratory results was performed using independent sample t-tests/Kruskal-Wallis tests, and χ2 tests or Fisher's exact tests.
After 12 weeks of treatment with spleen aminopeptide, there was a notable improvement in symptoms of nasal congestion when compared to the control group [M(Q1,Q3):2(1, 2) versus 2(1, 3), H=6.308, P value <0.05]. Additionally, symptoms such as sneezing [M(Q1,Q3):2(1, 2) versus 2(1, 3), H=5.245, P value <0.05], nasal itching [M(Q1,Q3):2(1, 2) versus 2(1, 3), H=4.966, P value <0.05], tearing [M(Q1,Q3):1(0, 2) versus 1(0, 3), H=4.664, P value <0.05], and runny nose [M(Q1,Q3):2(1, 2) versus 2(1, 3), H=5.41, P value <0.05] also showed significant improvement. Both the control and experimental groups experienced a significant increase in nasal and ocular symptom scores after 12 weeks compared to their baseline measurements (P value <0.05).  In the experimental group, there was a notable increase in nasal congestion [M(Q1,Q3):1(0, 1) versus 1(0, 2), H=4.042, P value <0.05], as well as in the scores for eye itching, foreign body sensation, and redness [M(Q1,Q3):1(0, 2) versus 1(0, 2), H=5.302, P value <0.05]. The total symptom scores also showed a significant rise [M(Q1,Q3):4(-1, 9) versus 5(0, 12.5), H=3.958, P value <0.05]. After 6 weeks, the antihistamine drug score in the splenic peptide treatment group was lower than that of the control group (H=4.232, P value <0.05). Following 12 weeks of treatment, both the total drug score [M(Q1,Q3):28.5(5, 77.5) versus 46(6, 155.5), H=3.995, P value <0.05] and the antihistamine drug score [M(Q1,Q3):10(0, 24) versus 19(2, 36.5), H=6.67, P value <0.05] were significantly reduced compared to the control group. Additionally, serum IL-17A levels in the treatment group were significantly lower than those in the control group after both 6 weeks (0.7±1.77 versus 0.85±1.67, H=10.08, P value <0.05) and 12 weeks (0.81±1.63 versus 0.94±1.73, H=5.196, P value <0.05) of splenic aminopeptide treatment.
The above study demonstrated that starting early treatment with a spleen aminopeptide oral solution can significantly help relieve nasal and eye symptoms for patients facing seasonal allergic rhinitis. This approach reduces the need for medications during flare-ups and improves the overall quality of life. It might also provide an immunomodulatory effect by decreasing serum IL-17A levels in patients.